Studysummary This review examines the JAK/STAT signaling pathway's significance in inflammatory skin diseases and evaluates the efficacy and safety of oral and topical JAK inhibitors for treating vitiligo and alopecia areata. Results are not reported in this study.
Read the full study on sciencedirect.com →
Research cited in this study 36
- Pro-Inflammatory Vδ1+ T-Cells Infiltrates Are Present In And Around The Hair Bulbs Of Non-Lesional And Lesional Alopecia Areata Hair Follicles Journal of Dermatological Science · 2020
- Response of Alopecia Areata of the Beard to Oral Tofacitinib Journal of the American Academy of Dermatology · 2019
- A Pilot Study of 2% Tofacitinib Cream with Narrowband Ultraviolet B for the Treatment of Facial Vitiligo Journal of The American Academy of Dermatology · 2019
- JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology · 2019
- Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
- Rebound Effect Associated with JAK Inhibitor Use in the Treatment of Alopecia Areata Journal of the European Academy of Dermatology and Venereology · 2018
- Topical Tofacitinib Solution for the Treatment of Alopecia Areata Affecting Eyelashes JAAD Case Reports · 2018
- Tofacitinib for the Treatment of Alopecia Areata in Preadolescent Children Journal of the American Academy of Dermatology · 2018
- Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
- Successful Treatment of Severe Alopecia Areata With Oral or Topical Tofacitinib PubMed · 2018
- Simultaneous Improvement of Alopecia Universalis and Atopic Dermatitis in a Patient Treated with a JAK Inhibitor JAAD case reports · 2018
- Topical 2% Tofacitinib for Children with Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Journal of the American Academy of Dermatology · 2018
- An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis Journal of Investigative Dermatology · 2018
- Treatment of Vitiligo with the Topical Janus Kinase Inhibitor Ruxolitinib: A 32-Week Open-Label Extension Study with Optional Narrow-Band Ultraviolet B Journal of the American Academy of Dermatology · 2018
- Tofacitinib (Selective Janus Kinase Inhibitor 1 and 3): A Promising Therapy for the Treatment of Alopecia Areata: A Case Report of Six Patients International Journal of Trichology · 2018
- Tofacitinib 2% Ointment, a Topical Janus Kinase Inhibitor, for the Treatment of Alopecia Areata: A Pilot Study of 10 Patients Journal of the American Academy of Dermatology · 2017
- Oral Tofacitinib: A Promising Treatment in Atopic Dermatitis, Alopecia Areata, and Vitiligo Clinical and Experimental Dermatology · 2017
- Complete Regrowth of Beard Hair with Ruxolitinib in an Alopecia Universalis Patient Skin appendage disorders · 2017
- A Case of Topical Ruxolitinib Treatment Failure in Alopecia Areata Journal of cutaneous medicine and surgery · 2017
- Topical Janus Kinase Inhibitors for the Treatment of Pediatric Alopecia Areata Journal of the American Academy of Dermatology · 2017
- Treatment of Alopecia Areata With Tofacitinib JAMA Dermatology · 2017
- Two Cases of Alopecia Areata Treated with Ruxolitinib: A Discussion of Ideal Dosing and Laboratory Monitoring International Journal of Dermatology · 2017
- Experience with Oral Tofacitinib in 8 Adolescent Patients with Alopecia Universalis Journal of the American Academy of Dermatology · 2017
- Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.) · 2017
- Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients Journal of The American Academy of Dermatology · 2016
- Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata JCI insight · 2016
- Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata JCI insight · 2016
- Successful Treatment of Refractory Alopecia Areata Universalis and Psoriatic Arthritis, But Not Plaque Psoriasis with Tofacitinib in a Young Woman Acta dermato-venereologica · 2016
- Treatment of an Alopecia Areata Patient with Tofacitinib Results in Regrowth of Hair and Changes in Serum and Skin Biomarkers Experimental Dermatology · 2016
- Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata Journal of the American Academy of Dermatology · 2015
- Topical Ruxolitinib for the Treatment of Alopecia Universalis JAMA dermatology · 2015
- Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth Science Advances · 2015
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib EBioMedicine · 2015
- Inhibiting Janus Kinases to Treat Alopecia Areata Nature medicine · 2014
- Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition Nature medicine · 2014
- Killing Two Birds with One Stone: Oral Tofacitinib Reverses Alopecia Universalis in a Patient with Plaque Psoriasis Journal of Investigative Dermatology · 2014